ZYNEX Obtains Medicare Accreditation

LITTLETON, Colo.--(Business Wire)--
Zynex, Inc. (OTCBB:ZYXI), a provider of pain management systems and
electrotherapy products for medical patients with functional disability,
announces it has obtained accreditation as a Medicare DMEPOS (Durable Medical
Equipment, Prosthetics, Orthotics, and Supplies) supplier, as required to
maintain its status as provider to Medicare and several private health insurance
companies. The accreditation was performed by the Compliance Team, one of ten
organizations certified to audit and accredit durable medical equipment
providers in the US.

Thomas Sandgaard, CEO of Zynex explains: "It was very important to us to obtain
this accreditation before the September 30 deadline. Not only do we maintain our
status of being a provider to Medicare, but our customers know that we have met
the high standards and procedures which are required for accreditation. Other
providers that are not able to comply with these standards will be excluded from
being a provider to Medicare and several private health insurance companies in
the future."

About Zynex

Zynex, Inc. (founded in 1996) engineers, manufactures, markets and sells its own
design of electrotherapy medical devices in two distinct markets: standard
digital electrotherapy products for pain relief and pain management; and the
NeuroMove(TM) for stroke and spinal cord injury (SCI) rehabilitation. Zynex's
product lines are fully developed, FDA-cleared, commercially sold, an have been
developed to uphold the Company's mission of improving the quality of life for
patients suffering from impaired mobility due to stroke, spinal cord injury, or
debilitating and chronic pain.

Safe Harbor Statement

Certain statements in this release are "forward-looking" and as such are subject
to numerous risks and uncertainties. Actual results may vary significantly from
the results expressed or implied in such statements. Factors that could cause
actual results to materially differ from forward-looking statements include, but
are not limited to, the need to obtain additional capital in order to grow our
business, larger competitors with greater financial resources, the need to keep
pace with technological changes, our dependence on the reimbursement from
insurance companies for products sold or rented to our customers, acceptance of
our products by health insurance providers, acceptance of our products by
hospitals and clinicians, our dependence on third party manufacturers to produce
our goods on time and to our specifications, implementation of our sales
strategy including a strong direct sales force, the uncertain outcome of pending
material litigation and other risks described in our 10-K Report for the year
ended December 31, 2008.

Zynex, Inc.
Thomas Sandgaard, 303-703-4906
CEO
www.zynexmed.com

Copyright Business Wire 2009